1. health and fitness

Netupitant-Palonosetron FDC Market Opportunities,
Demand and Forecasts, 2017 - 2027
April 2017
Report Id : REP-GB-3096
Status : Ongoing
Category : Healthcare, Pharmaceuticals & Medical Devices
©2015 Future Market Insights, All Rights Reserved
About
Future Market Insights
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom
research reports, and consulting services. We deliver a complete packaged solution, which
combines current market intelligence, statistical anecdotes, technology inputs, valuable growth
insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC,
ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy,
Technology, Healthcare, and Retail.
We have a global presence with delivery centers across India specializing in providing global
research reports and country research reports. FMI is headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning
from every corner of the world to distill it to one thing – the perfect solution for our client.
Research Capabilities




Customized
Research
Syndicated
Research
Investment
Research
Social Media
Research
Customized Research
Syndicated Research
Investment Research
Social Media Research
Sector Coverage




Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Subscription Information
For detailed subscription information please contact
Hari. T (Sr. Manager - Global Business Development)
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Email: hari.t@futuremarketinsights.com
©2015 Future Market Insights, All Rights Reserved
2
Research Methodology (1/2)
Systematic Research Approach
1
Market profiling
2
Formulating discussion guide
3
Developing list of respondents
4
In-depth secondary research is used to
ascertain overall market size, top
industry players, top products, industry
associations, etc.
PMR formulates a detailed discussion
guide to conduct expert and industry
interviews
PMR develops a list of industry players
(manufacturers), distributors, retailers
and industry experts
Data collection
PMR conducts interviews with industry
experts, industry players, distributors
and retailers
Data validation
Data is validated by triangulation
method, wherein secondary, primary
and PMR analysis contribute to the final
data
5
6
Data analysis
Insights
7
Data is scrutinized using MS-Excel to
obtain qualitative and quantitative
insights about the industry
PMR delivers industry insights and
information in the required format
(PDF)
Data
Collection




Research &
Intelligence
Data Filter
& Analysis
Identifying key opinion leaders
Questionnaire design
In-depth interviews
Coverage across value chain
Actionable
Insights
A
Primary
Research






B
SOLUTION





Market participants
Key strengths
Product portfolio
Mapping as per value chain
Key focus segments
Primary Research #




Linkedin
Zoominfo
Salesforce
Avention
Business
Solution
Desk
Research
C
Key industry experts
Channel study
Developments
Market dynamics
Products
Conclusions
Company
Analysis
Secondary Research #




Company websites
Company annual
reports
White papers
Financial reports
Paid Publications#




Factiva
GBI
Genios
Meltwater
# includes sources of databases
©2015 Future Market Insights, All Rights Reserved
3
Netupitant-Palonosetron FDC Market Opportunities, Demand and
Forecasts, 2017 - 2027
Netupitant-Palonosetron is the first approved fixed dose combination drug for the prevention of
chemotherapy induced nausea and vomiting. Cancer is a leading cause of death worldwide, accounting
nearly 1.4 million new cases in 2012. The most common type of cancer is lung cancer accounting about
1.59 million deaths, globally. Other prominent cancers are liver cancer, breast cancer, stomach cancer,
esophageal and stomach cancer. In 2012, nearly 8.2 million deaths occurred from aforementioned
indication, globally. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormone
therapy, targeted therapy, precision medicine and stem cell transplantation. The most common
treatment for cancer is chemotherapy; it uses drugs to kill cancer cells that cause pain and other
problems. Chemotherapy given before surgery and radiation therapy to make the tumor cell smaller is
known as neo-adjuvant chemotherapy and chemotherapy given after treatment with surgery or radiation
therapy is known as adjuvant chemotherapy.
Chemotherapy, not only kills the cancer cells but also attacks healthy cells that leads to side effects such
as fatigue, hair loss, nausea, and vomiting. Chemotherapy-Induced Nausea and Vomiting (CINV) is one of
the most serious side effects that is taken into account. Chemotherapy-induced nausea and vomiting are
classified as acute, that occurs within 24 hours of the treatment; anticipatory, that is triggered due to
some exposed stimuli; other are refractory; delayed and breakthrough. Incidence, timing, and intensity of
chemotherapy-induced nausea and vomiting vary on chemotherapeutic agents and patient factors. CINV
occurs in about 80% of patients and has a severe impact on patient’s life.
©2015 Future Market Insights, All Rights Reserved
4
Netupitant-Palonosetron FDC Market Opportunities, Demand and
Forecasts, 2017 - 2027
Fixes dose combination for the treatment of Chemotherapy-induced Nausea and Vomiting is said to be
effective and is expected to overcome the side-effects of chemotherapy. Netupitant – Palonosetron FDC
is approved by U.S Food and Drug Administration for the prevention of acute nausea and vomiting during
cancer treatment process. The therapeutic drug is the combination of two drugs, namely Netupitant and
Palonosetron. Palonosetron was approved by FDA in 2008. It is a serotonin subtype 3 (5-HT3) receptor
antagonis for the prevention of acute nausea and vomiting. Netupitant is a (NK1) receptor antagonist
given after the start of chemotherapy. Antiemetics are less effective in controlling nausea and vomiting
because the intensity is high than actual vomiting. Proper antiemetics can prevent CINV in about 60%70% of patients.
Request For Report Sample@ http://www.futuremarketinsights.com/toc/rep-gb-3096
Netupitant-Palonosetron FDC Market: Drivers and Restrains
According to Word Health Organization, it is estimated that by 2030, about 23.6 million new cases of
cancer will prevail worldwide. Netupitant-Palonosetron Fixed Dose Combination is expected to fulfill
unmet needs of the chemotherapy-induced nausea and vomiting therapeutics market. The fixed dose
combination studies has revealed positive results in clinical phase trials. The demand of this drug for
better treatment option by physician and patients will drive the market. Intense research and
development in cancer therapeutics, the rise in the incidence of cancer cases, increased preference
toward chemotherapy for the treatment of cancer and the use of chemotherapy in combination with
other cancer treatment are anticipated to fuel the growth of Netupitant-Palonosetron FDC Market.
©2015 Future Market Insights, All Rights Reserved
5
Netupitant-Palonosetron FDC Market Opportunities, Demand and
Forecasts, 2017 - 2027
Netupitant-Palonosetron FDC Market: Segmentation
The global Netupitant-Palonosetron FDC markethas been classified by distribution channel, and
geography.
Netupitant-Palonosetron FDC is an oral formulation with 300 mg netupitant/0.5 mg palonosetron.
Palonosetron is available in the market as a single agent while netupitant is a new therapeutic agent
available in combination with Palonosetron. Netupitant-Palonosetron fixed dose combination is likely to
overcome problems associated with chemotherapy treatment option available in the market currently.
Netupitant-Palonosetron FDC Market: Overview
Netupitant-Palonosetron FDC, a serotonin receptor antagonists and NK1 receptor antagonist. Serotonin
receptor antagonists blocks the binding of serotonin to its receptor, thus stopping the signal to the brain.
Based on the distribution channel the Netupitant-Palonosetron FDC Market is segmented into hospital
pharmacy, drug store, retail pharmacy, and online pharmacy. The rise in the incidence of cancer patient
population, funding by the governmental bodies for research and development on cancer therapeutics,
focus on acquisition and merger by various key manufacturers for product expansion and technology use
for drug development is attributed towards the growth of the target market.
©2015 Future Market Insights, All Rights Reserved
6
Netupitant-Palonosetron FDC Market Opportunities, Demand and
Forecasts, 2017 - 2027
Netupitant-Palonosetron FDC Market: Regional Overview
Region-wise, the global Netupitant-Palonosetron FDCMarket is classified into regions namely, North
America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.
More than 70% of world's cancer death occurs in Africa, Asia, and South America. Around 33% of cancer
cases worldwide are due to smoke and tobacco.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3096
Netupitant-Palonosetron FDC Market: Key Players
The market leader for Netupitant-Palonosetron FDC Market is Helsinn Birex Pharmaceuticals Ltd and
the drug is distributed and marketed by Eisai Inc.
©2015 Future Market Insights, All Rights Reserved
7
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
sales@futuremarketinsights.com
For media queries, contact the press office at
press@futuremarketinsights.com
For other queries contact:
Harish Tiwari
(General Manager & Global Head Business Development)
Future Market Insights: 3rd Floor,
207 Regent Street, London W1B 3HH
T: +44 20 7692 8790 | D: +44 20 3287 4268
Email: hari.t@futuremarketinsights.com
Thank You
Future Market Insights Global & Consulting Private Limited (FMI)
©2015 Future Market Insights, All Rights Reserved
8